LIPOOLIGOSACCHARIDE BIOSYNTHESIS IN NEISSERIACEAE

奈瑟菌科中脂寡糖的生物合成

• 批准号: 3453881
• 负责人: DANIEL C STEIN
• 金额: $ 8.73万
• 依托单位: UNIV OF MARYLAND, COLLEGE PARK
• 依托单位国家: 美国
• 财政年份: 1988
• 资助国家: 美国
• 起止时间: 1988-09-30 至 1993-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3453881
• 关键词: Escherichia coli; Neisseria gonorrhoeae; Neisseria meningitidis; bacterial DNA; bacterial antigens; bacterial genetics; bacterial meningitis; bacterial polysaccharides; carbohydrate biosynthesis; genetic library; genetic manipulation; genetic mapping; genetic strain; glycolipids; gonorrhea; lipid biosynthesis; lipopolysaccharides; molecular cloning; monoclonal antibody; mutant; oligosaccharides; surface antigens; transposon /insertion element

The ongoing epidemic of gonorrhea has made Neisseria zonorrhoeae one of the most important human pathogens. The total health care costs of the disease exceeds 1 billion dollars per year. A closely related pathogen, N. Meningitides, has a mortality rate of approximately 85% when left untreated, but can be less than 1% when vigorous antibiotic and support therapy is administered early. A wide variety of cell surfaces polymers have been implicated as virulence factors, and yet little is known of the pathogenesis of the two diseases. Lipooligosaccharides may be the most important surface antigen, with respect to adherence and susceptibility of the organism to the killing action of normal human serum. The work to be described in this proposal demonstrates how state of the art molecular biology techniques can be used to study lipooligosaccharide biosynthesis in these pathogens. The genes involved in the biosynthesis of the polysaccharide portion of this molecule will be identified by molecular cloning and reactivity with monoclonal antibodies. Mutants that no longer produce this lipooligosaccharide will be constructed. These strains will be used to elucidate the genetic basis of lipooligosaccharide biosynthesis.

淋病的持续流行使带状疱疹奈瑟菌 最重要的人类病原体之一 全面保健 每年的疾病费用超过10亿美元。 一 密切相关的病原体，N.脑膜炎，死亡率为 当不治疗时约为85%，但当不治疗时可小于1%。 早期给予强有力的抗生素和支持治疗。 一 各种各样的细胞表面聚合物被认为是 毒力因子，但很少有人知道的发病机制， 这两种疾病。 低聚糖可能是最重要的 表面抗原，就粘附和易感性而言， 对正常人血清的杀伤作用。 工作 本提案中所描述的内容展示了现有技术如何 分子生物学技术可以用来研究 这些病原体中的脂寡糖生物合成。 的基因 参与多糖部分的生物合成， 分子将通过分子克隆和反应性鉴定 单克隆抗体。 不再产生这种物质的突变体 将构建脂寡糖。 这些菌株将是 用于阐明脂寡糖的遗传基础 生物合成